Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Interest Expenses (2019 - 2022)

Keros Therapeutics (KROS) has disclosed Interest Expenses for 4 consecutive years, with $1000.0 as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Interest Expenses changed 0.0% year-over-year to $1000.0, compared with a TTM value of $1000.0 through Dec 2022, down 75.0%, and an annual FY2022 reading of $1000.0, down 75.0% over the prior year.
  • Interest Expenses was $1000.0 for Q1 2022 at Keros Therapeutics, roughly flat from $1000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $3000.0 in Q3 2019 and bottomed at $1000.0 in Q2 2020.
  • Average Interest Expenses over 4 years is $1500.0, with a median of $1000.0 recorded in 2020.
  • Peak annual rise in Interest Expenses hit 0.0% in 2020, while the deepest fall reached 50.0% in 2020.
  • Year by year, Interest Expenses stood at $3000.0 in 2019, then crashed by 66.67% to $1000.0 in 2020, then changed by 0.0% to $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022.
  • Business Quant data shows Interest Expenses for KROS at $1000.0 in Q1 2022, $1000.0 in Q4 2021, and $1000.0 in Q3 2021.